NCT02159547

Brief Summary

H0 hypothesis: IV dexketoprofen is equivalent to placebo in ceasing migraine attack in emergency department. H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
224

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2014

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 31, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 10, 2014

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
12 months until next milestone

Results Posted

Study results publicly available

July 23, 2015

Completed
Last Updated

July 23, 2015

Status Verified

June 1, 2015

Enrollment Period

3 months

First QC Date

May 31, 2014

Results QC Date

March 16, 2015

Last Update Submit

June 27, 2015

Conditions

Keywords

migraine, emergency department, dexketoprofen, placebo

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale Change

    Change from baseline in Visual Analogue Scale, 100 mm, at 45th minutes. Visual Analogue Scale is measurement tool scoring tool between 0 (no pain) and 100 mm (worst pain). Minimum clinically significant change in pain score is 13 or 16 mm.

    45 minutes

Secondary Outcomes (1)

  • Adverse Effects

    45th minutes

Study Arms (2)

Dexketoprofen

ACTIVE COMPARATOR

50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.

Drug: Dexketoprofen

normal slaline

PLACEBO COMPARATOR

50 ml normal saline

Other: Normal Saline

Interventions

50 mg intravenous arveles in 50 ml saline in 5 minutes

Also known as: Arveles
Dexketoprofen

50 ml normal saline

normal slaline

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients presented with headache who diagnosed as migraine attack according to the international headache society

You may not qualify if:

  • denied to give inform concent, illiterate patients, chronic renal failure, taking NSAIDs during the last six hours, pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Antalya Training and Govermental Hospital

Antalya, Turkey (Türkiye)

Location

Related Publications (1)

  • Turkcuer I, Serinken M, Eken C, Yilmaz A, Akdag O, Uyan E, Kiray C, Elicabuk H. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial. Emerg Med J. 2014 Mar;31(3):182-5. doi: 10.1136/emermed-2013-203044. Epub 2014 Jan 6.

    PMID: 24394884BACKGROUND

MeSH Terms

Conditions

Migraine DisordersEmergencies

Interventions

dexketoprofen trometamolSaline Solution

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Cenker EKEN
Organization
Akdeniz University

Study Officials

  • Faruk Gungor, Pyhsician

    Antalya Training and Govermental Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associated Proffesor

Study Record Dates

First Submitted

May 31, 2014

First Posted

June 10, 2014

Study Start

May 1, 2014

Primary Completion

August 1, 2014

Study Completion

August 1, 2014

Last Updated

July 23, 2015

Results First Posted

July 23, 2015

Record last verified: 2015-06

Locations